Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 15/20 | 0.56 |
| ▸ | BRD2 | P25440 | 6/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30545927 | 0.88 | BRD4 (0.61) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL22497644 | 0.88 | BRD4 (0.61) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL5503154 | 0.88 | BRD4 (0.57) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL15653363 | 0.82 | ALDH1A1 (0.56) | JAK2BRD4BRD2BRD3ERN1 | |
| SCHEMBL22855856 | 0.82 | JAK2 (0.51) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL18203036 | 0.82 | PTGS1 (0.43) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL16259209 | 0.81 | BRD4 (0.51) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL3885694 | 0.79 | BRD4 (0.66) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL20094000 | 0.79 | ERN1 (0.52) | JAK2BRD4BRD2BRD3CREBBP | |
| SCHEMBL29741402 | 0.79 | ERN1 (0.52) | JAK2BRD4BRD2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377443-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2022-07-05 | — | — | US | disclosed |
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | CellCentric Limited (GB) | 2020-12-31 | — | — | US | disclosed |
| EP-3529248-B1 | PHARMACEUTICAL COMPOUNDS | CELLCENTRIC LTD (GB) | 2020-08-19 | — | — | EP | disclosed |
| US-10696666-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2020-06-30 | — | — | US | disclosed |
| WO-2018073586-A1 | PHARMACEUTICAL COMPOUNDS | CELLCENTRIC LTD (GB) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | EP300, HDAC1, HDAC11 | JAK2 439/4885BRD4 23/4885BRD2 60/4885 |
| US-11377443-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | JAK2 439/4885BRD4 23/4885BRD2 60/4885 |
| US-10696666-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | JAK2 439/4885BRD4 23/4885BRD2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.